-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Director Robert W. Postma Buys 750,000 Shares
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Director Robert W. Postma Buys 750,000 Shares
Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Rating) Director Robert W. Postma bought 750,000 shares of the business's stock in a transaction on Tuesday, November 29th. The shares were acquired at an average cost of $0.65 per share, for a total transaction of $487,500.00. Following the transaction, the director now directly owns 5,000,000 shares in the company, valued at approximately $3,250,000. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.
Alaunos Therapeutics Stock Performance
TCRT stock opened at $0.64 on Friday. The firm has a 50 day moving average of $1.25 and a 200 day moving average of $1.41. Alaunos Therapeutics, Inc. has a 52 week low of $0.41 and a 52 week high of $4.01.
Get Alaunos Therapeutics alerts:Wall Street Analyst Weigh In
Separately, Wells Fargo & Company reaffirmed an "overweight" rating and issued a $3.00 price objective on shares of Alaunos Therapeutics in a research report on Tuesday, October 4th.
Institutional Trading of Alaunos Therapeutics
A number of institutional investors have recently bought and sold shares of the stock. E Fund Management Co. Ltd. acquired a new stake in Alaunos Therapeutics in the 3rd quarter worth approximately $26,000. SevenBridge Financial Group LLC acquired a new stake in Alaunos Therapeutics in the 3rd quarter worth approximately $34,000. UBS Group AG boosted its stake in Alaunos Therapeutics by 7.6% in the 3rd quarter. UBS Group AG now owns 288,597 shares of the company's stock worth $496,000 after purchasing an additional 20,422 shares in the last quarter. Nicolet Advisory Services LLC acquired a new stake in Alaunos Therapeutics in the 2nd quarter worth approximately $30,000. Finally, BNP Paribas Arbitrage SNC boosted its stake in Alaunos Therapeutics by 67.5% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 58,847 shares of the company's stock worth $101,000 after purchasing an additional 23,704 shares in the last quarter. 33.88% of the stock is currently owned by institutional investors and hedge funds.About Alaunos Therapeutics
(Get Rating)
Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors.
Featured Articles
- Get a free copy of the StockNews.com research report on Alaunos Therapeutics (TCRT)
- Ford Revving Up Production Of EV Power Units At U.K. Plant
- Are the Short Sellers Still Right About Mullen Automotive stock?
- La-Z-Boy Reclines To More Comfortable Levels
- Is Apple Going To Rally Into Year End?
- Is The Recovery Rally Here For SoFi?
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Get Rating) Director Robert W. Postma bought 750,000 shares of the business's stock in a transaction on Tuesday, November 29th. The shares were acquired at an average cost of $0.65 per share, for a total transaction of $487,500.00. Following the transaction, the director now directly owns 5,000,000 shares in the company, valued at approximately $3,250,000. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.
纳斯达克(代码：TCRT-GET评级)董事在11月29日星期二的一笔交易中购买了750,000股该公司的股票。这些股票是以每股0.65美元的平均成本收购的，总交易额为487,500.00美元。交易完成后，董事现在直接拥有该公司500万股股份，价值约325万美元。此次收购是在提交给美国证券交易委员会的一份文件中披露的，该文件可在此超链接.
Alaunos Therapeutics Stock Performance
ALaunos治疗公司股票表现
TCRT stock opened at $0.64 on Friday. The firm has a 50 day moving average of $1.25 and a 200 day moving average of $1.41. Alaunos Therapeutics, Inc. has a 52 week low of $0.41 and a 52 week high of $4.01.
TCRT股票周五开盘报0.64美元。该公司的50日移动均线切入位在1.25美元，200日移动均线切入位在1.41美元。ALaunos治疗公司的股价为0.41美元，为52周低点，52周高点为4.01美元。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
Separately, Wells Fargo & Company reaffirmed an "overweight" rating and issued a $3.00 price objective on shares of Alaunos Therapeutics in a research report on Tuesday, October 4th.
另外，富国银行(Wells Fargo&Company)在10月4日(星期二)的一份研究报告中重申了“增持”评级，并对ALaunos治疗公司的股票发布了3.00美元的目标价。
Institutional Trading of Alaunos Therapeutics
ALaunos治疗公司的机构交易
About Alaunos Therapeutics
ALaunos治疗公司简介
(Get Rating)
(获取评级)
Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors.
ALaunos治疗公司是一家专注于临床阶段肿瘤学的细胞治疗公司，开发采用TCR工程的T细胞疗法。该公司开发了TCR文库，该文库对10个对突变的KRAS、TP53和EGFR产生反应的TCR进行了I/II期临床试验，这些TCR文库用于治疗非小细胞肺癌、结直肠癌、子宫内膜癌、胰腺癌、卵巢癌和胆管癌；人类肿瘤抗原T细胞受体平台HunTR；以及用于治疗实体肿瘤的MBIL-15。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Alaunos Therapeutics (TCRT)
- Ford Revving Up Production Of EV Power Units At U.K. Plant
- Are the Short Sellers Still Right About Mullen Automotive stock?
- La-Z-Boy Reclines To More Comfortable Levels
- Is Apple Going To Rally Into Year End?
- Is The Recovery Rally Here For SoFi?
- 免费获取StockNews.com关于ALaunos治疗公司(TCRT)的研究报告
- 福特在英国工厂加速生产电动汽车动力装置
- 卖空者对马伦汽车股票的看法仍然正确吗？
- La-Z-Boy倾斜到更舒适的水平
- 苹果会在年底前大涨吗？
- 复苏集会是为SoFi而来的吗？
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受ALaunos治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对ALaunos治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧